Table 3.
Morphometric and echocardiographic characteristics of mice subjected to sham or MI surgery and treated for 3 weeks with AAV9-MCS or AAV9-miR-106b~25.
| Sham | MI | |||
|---|---|---|---|---|
| AAV9-MCS | AAV9- miR-106~25 | AAV9-MCS | AAV9- miR-106~25 | |
| n | 8 | 8 | 8 | 8 |
| BW (g) | 22.8 ± 2.1 | 25.3 ± 2.0 | 23.8 ± 1.5 | 24.3 ± 1.7 |
| LV mass (mg) | 84 ± 3 | 90 ± 2 | 88 ± 5 | 107 ± 4*# |
| LV mass/BW (mg/g) | 3.2 ± 0.2 | 3.8 ± 0.4 | 5.2 ± 0.4* | 6.4 ± 1.0* |
| IVSd (mm) | 0.79 ± 0.03 | 0.81 ± 0.02 | 0.75 ± 0.03 | 0.90 ± 0.03*# |
| IVSs (mm) | 1.18 ± 0.05 | 1.23 ± 0.07 | 1.10 ± 0.04 | 1.40 ± 0.06*# |
| LVIDd (mm) | 3.62 ± 0.07 | 3.78 ± 0.10 | 4.53 ± 0.19* | 4.00 ± 0.02# |
| LVIDs (mm) | 2.42 ± 0.13 | 2.56 ± 0.14 | 3.55 ± 0.20* | 2.79 ± 0.26# |
| LVPWd (mm) | 0.88 ± 0.03 | 0.86 ± 0.05 | 0.55 ± 0.05* | 0.87 ± 0.10# |
| LVPWs (mm) | 1.16 ± 0.05 | 1.21 ± 0.06 | 0.69 ± 0.07* | 1.05 ± 0.13# |
| EF (%) | 69 ± 4 | 67 ± 3 | 52 ± 2* | 65 ± 4*# |
| FS (%) | 33 ± 3 | 31 ± 2 | 22 ± 1* | 31 ± 3*# |
Data are expressed as means ± SEM.
BW body weight, LV left ventricular, IVSd interventricular septal thickness at end-diastole, IVSs interventricular septal thickness at end-systole, LVIDd left ventricular internal dimension at end-diastole, LVIDs left ventricular internal dimension at end-systole, LVPwd left ventricular posterior wall thickness at end-diastole, LVPws left ventricular posterior wall thickness at end-systole, EF ejection fraction, FS fractional shortening, E/A Doppler E/A ratio.
*Indicates P < 0.05 vs sham group subjected to treatment with a control antagomir.
#Indicates P < 0.05 vs experimental group.